Physician profile
David E Schleinkofer
NPI 1326030297
$19,300.40
in general payments reported to CMS, 2019-2025
20 companies · $5,999 in 2025
The $5,999 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,823 · 2020: $332 · 2021: $594 · 2022: $2,774 · 2023: $4,712 · 2024: $3,066 · 2025: $5,999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $10K · Food and Beverage: $3,650 · Education: $70.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $10,056.18 |
| Food and Beverage | $3,650.49 |
| Education | $70.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $7,181.63 | 2022-2025 | Solia, Selectra, Biomonitor |
| Medtronic, INC. | $6,490.10 | 2021-2025 | Evera Mri Xt Dr Surescan, Selectsecure, Linq II |
| Abbott Laboratories | $3,187.51 | 2019-2025 | Aveir, Jot Dx, Livewire |
| Medtronic Vascular, INC. | $1,425.88 | 2019-2020 | |
| Zoll Respicardia, INC. | $246.80 | 2021 | |
| Philips North America LLC | $150.00 | 2019 | |
| Amgen INC. | $121.60 | 2024 | Repatha |
| Janssen Pharmaceuticals, INC | $109.65 | 2019-2022 | |
| Boston Scientific Corporation | $81.73 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $69.69 | 2023-2024 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $45.30 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $40.55 | 2022-2025 | Verquvo |
| Angiodynamics, INC. | $31.90 | 2024 | Auryon Laser System 100-120 Vac |
| Amarin Pharma, INC. | $29.68 | 2020-2021 | |
| Novo Nordisk INC | $23.68 | 2024 | Ozempic |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.01 | 2022 | |
| Pfizer INC. | $14.04 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $13.59 | 2023 | Inpefa |
| Altathera Pharmaceuticals LLC | $13.03 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $7.03 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schleinkofer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.